Patents by Inventor Mark Gary Bock

Mark Gary Bock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Aza Compounds as IRAK-4 Inhibitors
    Publication number: 20180208605
    Abstract: The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 26, 2018
    Inventors: Venkateshwar Rao GUMMADI, Susanta SAMAJDAR, Subhendu MUKHERJEE, Mark Gary BOCK
  • Compounds and compositions as inhibitors of MEK
    Patent number: 10011599
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: July 3, 2018
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
  • CARBAMATE/UREA DERIVATIVES
    Publication number: 20170275264
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 28, 2017
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Haiyang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK
    Publication number: 20170183348
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 29, 2017
    Inventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar Panigrahi, Ramulu PODDUTOORI, Susanta SAMAJDAR
  • Compounds and compositions as inhibitors of MEK
    Patent number: 9629836
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 25, 2017
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
  • Carbamate/urea derivatives
    Patent number: 9624192
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 18, 2017
    Assignee: Novartis AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
  • CARBAMATE/UREA DERIVATIVES
    Publication number: 20160244426
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 25, 2016
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK
    Publication number: 20160136150
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 19, 2016
    Applicant: NOVARTIS AG
    Inventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar PANIGRAHI, Ramulu PODDUTOORI, Susanta SAMAJDAR
  • 17a-hydroxylase/C17,20-lyase inhibitors
    Patent number: 9339501
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 17, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • Carbamate/urea derivatives
    Patent number: 9273026
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 1, 2016
    Assignee: Novartis AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Hayang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
  • Compounds and compositions as inhibitors of MEK
    Patent number: 9227969
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: January 5, 2016
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
  • Spirohydantoin compounds and their use as selective androgen receptor modulators
    Publication number: 20150299120
    Abstract: The present invention relates to a compound of formula (I-1) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 1, 2013
    Publication date: October 22, 2015
    Inventors: Mark Gary BOCK, Chetan PANDIT, Sanjita SASMAL, Thomas ULLRICH
  • CARBAMATE/UREA DERIVATIVES
    Publication number: 20150218127
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 14, 2015
    Publication date: August 6, 2015
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Telin WANG, Xiaoyang WANG, Xuechun ZHANG
  • 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
    Publication number: 20150209356
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Application
    Filed: April 9, 2015
    Publication date: July 30, 2015
    Applicant: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • Pyrazoline derivatives and their use as selective androgen receptor modulators
    Patent number: 9051326
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: June 9, 2015
    Assignee: NOVARTIS AG
    Inventors: Mark Gary Bock, Bharat Lagu, Chetan Pandit, Sanjita Sasmal, Thomas Ullrich
  • Carbamate/urea derivatives
    Patent number: 9034874
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: May 19, 2015
    Assignee: NOVARTIS AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tielin Wang, Xiaoyang Wang, Xuechun Zhang
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 9029399
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 12, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Saumitra Sengupta
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK
    Publication number: 20150051209
    Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 19, 2015
    Applicant: NOVARTIS AG
    Inventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar PANIGRAHI, Ramulu PODDUTOORI, Susanta SAMAJDAR
  • 17?-hydroxylase/C-lyase inhibitors
    Patent number: 8946260
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
  • Triazine-oxadiazoles
    Publication number: 20150025057
    Abstract: The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 22, 2015
    Applicant: NOVARTIS AG
    Inventors: Oliver BARKER, Jonathan Mark BENTLY, Mark Gary BOCK, Thomas CAIN, Praful CHOVATIA, Jennifer Ruth DOD, Florence EUSTACHE, Laura GLEAVE, Jonathan HARGRAVE, Alexander HEIFETZ, Richard LAW, Ali RAOOF, David WILLOWS